Saturday 17 October 2026
Export IMRN’s income statement to Excel — free account
IMMURON
IMRN Healthcare Biotechnology
IMMURON’s revenue for fiscal 2026 (year ended June 2026) was $5.2 million, up 10.9% from fiscal 2025. Revenue growth for five consecutive years.
0.98
0.05
−4.85%
Follow IMRN
| Jun '26 | Jun '25 | Jun '24 | Jun '23 | Jun '22 | Jun '21 | Jun '20 | Jun '19 | Jun '18 | Jun '17 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
5 | 2 | 3 | 4 | 4 | 3 | 5 | 3 | — | — |
P/S ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
89.24 | (2.11) | (1.38) | (2.32) | 1.06 | 6.60 | (2.69) | (4.70) | 8.91 | — |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
(3.47) | (1.01) | (4.35) | (7.30) | (24.73) | (10.00) | (0.63) | 0.00 | 0.00 | 0.00 |
EV/EBITDA |
0.93 | 0.27 | 1.16 | 1.95 | 2.45 | 2.86 | 0.33 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
0.58 | 0.15 | 1.00 | 1.99 | 1.77 | 2.27 | 0.45 | 0.54 | 0.00 | 0.00 |
EV/FCF |
0.58 | 0.15 | 1.00 | 1.99 | 1.77 | 2.27 | 0.45 | 0.54 | 0.00 | 0.00 |
Quick Ratio |
5.84 | 2.42 | 4.83 | 8.75 | 15.15 | 22.63 | 6.93 | 5.09 | 7.98 | 3.37 |
Current Ratio |
7.26 | 5.09 | 5.46 | 9.20 | 15.75 | 22.96 | 8.54 | 5.59 | 8.78 | 4.83 |
Net Debt/EBITDA |
1.81 | 0.42 | 1.27 | 5.40 | 7.78 | 3.00 | 1.13 | 1.11 | 1.66 | 0.58 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1.69% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 |
Asset Turnover |
0.68 | 0.56 | 0.26 | 0.07 | 0.03 | 0.01 | 0.33 | 0.26 | 0.21 | 0.34 |
Operating CF/Net income |
0.89 | 1.18 | 0.85 | 0.69 | 1.10 | 0.49 | 1.08 | 0.39 | 1.17 | 1.03 |
Capex/Depreciation |
(0.11) | 0.00 | 0.00 | (0.16) | (0.38) | (0.15) | (0.02) | (0.39) | (1.38) | (1.16) |
Interest Coverage |
(340.75) | (930.89) | (1,207.90) | (369.62) | (462.69) | (905.69) | — | — | (2,483.44) | (777.96) |
| (39.02%) | (49.82%) | (42.24%) | (16.98%) | (11.45%) | (54.15%) | (43.45%) | (56.16%) | (40.60%) | (118.87%) | |
| (32.26%) | (40.31%) | (36.39%) | (15.53%) | (10.83%) | (51.40%) | (38.21%) | (49.86%) | (34.81%) | (164.22%) | |
ROIC |
(146.14%) | (80.60%) | (547.06%) | (357.94%) | (168.08%) | (618.08%) | (76.44%) | (129.77%) | (47.94%) | (153.23%) |
Return on Tangible Assets |
(32.91%) | (63.90%) | (56.95%) | (20.59%) | (12.74%) | (33.99%) | (73.86%) | (84.17%) | (35.68%) | (103.49%) |
Average Days of Receivables |
66.68 | 96.45 | 103.30 | 84.42 | 316.21 | 838.26 | 47.48 | 148.14 | 333.40 | 462.27 |
Research and Development Expense of Revenue |
25.06% | 49.37% | 109.64% | 143.63% | 85.97% | 938.02% | 46.80% | 43.75% | 122.48% | 331.66% |
Selling, General and Administrative Expense of Revenue |
100.82% | 108.91% | 134.32% | 285.28% | 515.06% | 4,379.16% | 160.48% | 246.24% | 183.07% | 305.74% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
1.15% | 4.17% | 0.07% | 12.58% | 12.39% | 1,451.88% | (21.20%) | 56.28% | 0.00% | 37.43% |
Graham Net Nets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(1.94%) | (1.18%) | (0.91%) | (1.02%) | (1.77%) | (0.92%) | (0.47%) | (0.73%) | (1.09%) | (1.14%) |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Revenue per Share |
0.70 | 0.82 | 0.56 | 0.21 | 0.10 | 0.02 | 0.38 | 0.47 | 0.43 | 0.40 |
Operating CF per Share |
(0.30) | (0.69) | (0.68) | (0.31) | (0.40) | (0.55) | (0.48) | (0.36) | (0.82) | (2.00) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(0.30) | (0.69) | (0.68) | (0.31) | (0.40) | (0.55) | (0.48) | (0.36) | (0.82) | (2.00) |
Cash per Share |
0.82 | 0.32 | 1.34 | 2.25 | 2.82 | 3.39 | 0.49 | 1.01 | 1.10 | 1.14 |
Shareholders Equity per Share |
1.02 | 0.91 | 1.46 | 2.32 | 2.96 | 3.50 | 0.86 | 1.45 | 1.96 | 1.87 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.02 | 0.91 | 1.46 | 2.32 | 2.96 | 3.50 | 0.86 | 1.45 | 1.96 | 1.87 |
Free Cash Flow |
(2.22) | (3.97) | (3.86) | (1.75) | (2.29) | (3.05) | (2.11) | (1.29) | (2.74) | (5.30) |
Working Capital |
7.58 | 5.21 | 7.89 | 12.25 | 16.08 | 18.40 | 2.61 | 3.92 | 4.84 | 4.94 |
Capital Expenditures |
0.00 | — | 0.00 | (0.01) | (0.01) | 0.00 | 0.00 | 0.00 | (0.01) | 0.00 |
Net Current Asset Value |
7.45 | 5.15 | 7.79 | 12.14 | 15.96 | 18.38 | 2.59 | 3.91 | 4.84 | 4.94 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
4.56 | 0.44 | 0.30 | 0.24 | 0.12 | 1.29 | 0.62 | 0.31 | 0.00 | 0.26 |
Cash ROIC |
(16.17%) | (56.31%) | (24.13%) | (6.74%) | (6.97%) | (8.02%) | (35.39%) | (14.44%) | (26.84%) | (65.70%) |
Accounts Receivable Turnover |
4.75 | 4.38 | 5.40 | 3.19 | 1.52 | 0.46 | 3.70 | 1.71 | 1.08 | 0.46 |
Accounts Payable Turnover |
1.95 | 1.37 | 0.93 | 0.41 | 0.25 | 0.09 | 0.89 | 0.73 | 0.42 | 0.24 |
Inventory Turnover |
1.38 | 1.49 | 1.28 | 0.83 | 0.77 | 0.10 | 1.00 | 1.23 | 0.30 | 0.15 |
Average Days of Payables |
179.34 | 221.36 | 497.81 | 878.58 | 1,753.58 | 5,414.80 | 203.65 | 597.17 | 600.91 | 1,434.33 |
Days of Inventory on Hand |
303.08 | 256.52 | 369.34 | 618.73 | 493.26 | 2,088.72 | 422.60 | 297.70 | 434.04 | 2,525.89 |
Average Receivables |
1.10 | 1.08 | 0.60 | 0.38 | 0.37 | 0.24 | 0.46 | 1.00 | 1.32 | 2.30 |
Average Payables |
0.95 | 1.20 | 1.10 | 0.82 | 0.70 | 0.41 | 0.52 | 0.66 | 0.77 | 1.06 |
Average Inventory |
1.35 | 1.09 | 0.80 | 0.40 | 0.23 | 0.38 | 0.46 | 0.39 | 1.07 | 1.65 |
Average Assets |
7.74 | 8.38 | 12.50 | 16.42 | 19.12 | 12.19 | 5.14 | 6.64 | 6.71 | 3.12 |
Average Common Equity |
6.40 | 6.78 | 10.77 | 15.01 | 18.08 | 11.57 | 4.52 | 5.90 | 5.75 | 4.32 |
Columns are period end dates · fundamentals updated 6 Oct 2026